PE20121613A1 - Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 - Google Patents

Derivados de quinolina amida como moduladores alostericos positivos de receptores m1

Info

Publication number
PE20121613A1
PE20121613A1 PE2012000830A PE2012000830A PE20121613A1 PE 20121613 A1 PE20121613 A1 PE 20121613A1 PE 2012000830 A PE2012000830 A PE 2012000830A PE 2012000830 A PE2012000830 A PE 2012000830A PE 20121613 A1 PE20121613 A1 PE 20121613A1
Authority
PE
Peru
Prior art keywords
quinoline
alkyl
receptors
halogen
derivatives
Prior art date
Application number
PE2012000830A
Other languages
English (en)
Inventor
Scott D Kududk
Kelly-Ann Schlegel
Zhi-Qiang Yang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20121613A1 publication Critical patent/PE20121613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE QUINOLINA DE FORMULA (I), DONDE X1 ES N O N-O; X2-X3 ES -CH2-CH2-, -O-CH2, -CH2-O- O CH2; X4, X5, X6 Y X7 SON N, N-O, CH, O; R1 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R2A Y R2B SON H, OH, HALOGENO, JUNTOS FORMAN =O; R3 ES HALOGENO, O-ALQUILO C1-C6, S-ALQUILO C1-C6, ENTRE OTROS; R4 ES OH, HALOGENO, ALQUILO C1-C6, O-ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[(6-CLOROPIRIDIN-3-IL)METIL]-N-[(1S,2S)-2-HIDROXICICLOHEXIL]QUINOLINA-2-CARBOXAMIDA, N-[(1S,2S)-2-HIDROXICICLOHEXIL]-4-[(6-METILPIRIDIN-3-IL)METIL]QUINOLINA-2-CARBOXAMIDA, N-[(1S,2S)-2-HIDROXICICLOHEXIL]-4-(PIRIDIN-3-ILMETIL)QUINOLINA-2-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES ALOSTERICOS POSITIVOS DE LOS RECEPTORES M1 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS TALES COMO LA ENFERMEDAD DE ALZHEIMER, ESQUIZOFRENIA, TRASTORNOS DEL DOLOR O DEL SUENO
PE2012000830A 2009-12-17 2010-12-13 Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 PE20121613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28753509P 2009-12-17 2009-12-17

Publications (1)

Publication Number Publication Date
PE20121613A1 true PE20121613A1 (es) 2012-12-02

Family

ID=44305688

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000830A PE20121613A1 (es) 2009-12-17 2010-12-13 Derivados de quinolina amida como moduladores alostericos positivos de receptores m1

Country Status (41)

Country Link
US (2) US9199939B2 (es)
EP (1) EP2512243B1 (es)
JP (1) JP5651708B2 (es)
KR (1) KR101494059B1 (es)
CN (1) CN102651970B (es)
AR (1) AR079510A1 (es)
AU (1) AU2010340142B2 (es)
BR (1) BR112012014180A2 (es)
CA (1) CA2782347C (es)
CL (1) CL2012001605A1 (es)
CO (1) CO6551729A2 (es)
CR (1) CR20120327A (es)
CY (1) CY1117726T1 (es)
DK (1) DK2512243T3 (es)
DO (1) DOP2012000167A (es)
EA (1) EA022494B1 (es)
EC (1) ECSP12011983A (es)
ES (1) ES2575154T3 (es)
GE (1) GEP201606506B (es)
GT (1) GT201200201A (es)
HN (1) HN2012001265A (es)
HR (1) HRP20160574T1 (es)
HU (1) HUE029734T2 (es)
IL (1) IL220130A0 (es)
MA (1) MA33920B1 (es)
ME (1) ME02421B (es)
MX (1) MX336774B (es)
NI (1) NI201200107A (es)
NZ (1) NZ600674A (es)
PE (1) PE20121613A1 (es)
PH (1) PH12012501222A1 (es)
PL (1) PL2512243T3 (es)
PT (1) PT2512243E (es)
RS (1) RS54798B1 (es)
SG (1) SG181719A1 (es)
SI (1) SI2512243T1 (es)
TN (1) TN2012000231A1 (es)
TW (1) TWI412525B (es)
UA (1) UA106406C2 (es)
WO (1) WO2011084368A1 (es)
ZA (1) ZA201204313B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2011215704B2 (en) * 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
WO2012158474A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
EP2821401B1 (en) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
EP2921480B1 (en) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
BR112016006154A2 (pt) 2013-09-27 2017-08-01 Hoffmann La Roche derivados de indol e indazol
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN105793259A (zh) * 2014-01-22 2016-07-20 豪夫迈·罗氏有限公司 氟-萘基衍生物
JP6571077B2 (ja) * 2014-06-13 2019-09-04 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
CR20170566A (es) 2015-06-09 2018-03-20 Bayer Pharma AG Moduladores alostéricos positivos del receptor muscarínico m2
EA033826B1 (ru) * 2015-09-10 2019-11-29 Suven Life Sciences Ltd Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
WO2017099969A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Tetrahydroquinoxaline m1 receptor positive allosteric modulators
EA201891854A1 (ru) 2016-02-16 2019-01-31 Вандербилт Юниверсити Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
RS60875B1 (sr) 2016-09-02 2020-11-30 Suven Life Sciences Ltd Pozitivni alosterni modulatori muskarinskog m1 receptora
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
WO2018063552A1 (en) 2016-09-30 2018-04-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
SI3643718T1 (sl) 2017-06-20 2023-11-30 Takeda Pharmaceutical Company Limited Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1
CA3068209A1 (en) * 2017-06-20 2018-12-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
SG11202003471XA (en) * 2017-10-27 2020-05-28 Suven Life Sciences Ltd Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
JP7443238B2 (ja) * 2018-09-28 2024-03-05 武田薬品工業株式会社 複素環化合物
US12162864B2 (en) 2018-09-28 2024-12-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
MA53917A (fr) 2018-10-17 2022-01-26 Suven Life Sciences Ltd Dérivés de pyrrolo-pyridazine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
WO2020086864A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
WO2002018344A1 (en) * 2000-08-29 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel ester or amide derivatives
EP1596867A4 (en) 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
DE602004025508D1 (de) 2003-12-23 2010-03-25 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
JP2007529512A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
CN101321733A (zh) * 2005-12-05 2008-12-10 默克公司 喹诺酮m1受体阳性变构调节剂
US8106073B2 (en) * 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
CA2716921A1 (en) * 2008-03-21 2009-09-24 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
US8557832B2 (en) 2008-11-20 2013-10-15 Merck Sharp & Dohme Corp. Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators
EP2398324B1 (en) 2009-02-23 2014-09-03 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
KR101651312B1 (ko) 2009-08-31 2016-08-25 머크 샤프 앤드 돔 코포레이션 피라닐 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제
EP2490692B1 (en) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
US8664387B2 (en) 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
EP2515656B1 (en) 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
WO2011149801A1 (en) 2010-05-28 2011-12-01 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
US8557992B2 (en) 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
WO2012158474A1 (en) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
EA022494B1 (ru) 2016-01-29
HUE029734T2 (en) 2017-03-28
DOP2012000167A (es) 2012-12-31
MX336774B (es) 2016-01-28
DK2512243T3 (en) 2016-07-25
AU2010340142A1 (en) 2012-06-14
ECSP12011983A (es) 2012-07-31
RS54798B1 (sr) 2016-10-31
CO6551729A2 (es) 2012-10-31
AU2010340142B2 (en) 2014-05-08
NZ600674A (en) 2013-05-31
AR079510A1 (es) 2012-02-01
GEP201606506B (en) 2016-07-11
HK1170122A1 (zh) 2013-02-22
KR20120084324A (ko) 2012-07-27
HN2012001265A (es) 2015-09-07
US20160075656A1 (en) 2016-03-17
ME02421B (me) 2016-09-20
CN102651970A (zh) 2012-08-29
GT201200201A (es) 2015-05-20
EA201290519A1 (ru) 2013-01-30
EP2512243B1 (en) 2016-04-06
WO2011084368A1 (en) 2011-07-14
TW201130824A (en) 2011-09-16
JP5651708B2 (ja) 2015-01-14
TN2012000231A1 (en) 2013-12-12
CA2782347C (en) 2014-09-23
BR112012014180A2 (pt) 2015-09-15
PT2512243E (pt) 2016-06-08
CN102651970B (zh) 2014-11-12
ZA201204313B (en) 2016-01-27
ES2575154T3 (es) 2016-06-24
IL220130A0 (en) 2012-07-31
UA106406C2 (ru) 2014-08-26
MA33920B1 (fr) 2013-01-02
EP2512243A1 (en) 2012-10-24
CY1117726T1 (el) 2017-05-17
US9199939B2 (en) 2015-12-01
CR20120327A (es) 2012-07-30
CA2782347A1 (en) 2011-07-14
TWI412525B (zh) 2013-10-21
EP2512243A4 (en) 2013-05-29
CL2012001605A1 (es) 2012-10-05
US20120252808A1 (en) 2012-10-04
HRP20160574T1 (hr) 2016-06-17
MX2012007013A (es) 2012-07-03
JP2013514358A (ja) 2013-04-25
KR101494059B1 (ko) 2015-02-16
PH12012501222A1 (en) 2012-11-05
PL2512243T3 (pl) 2016-09-30
SI2512243T1 (sl) 2016-07-29
SG181719A1 (en) 2012-07-30
NI201200107A (es) 2012-10-30

Similar Documents

Publication Publication Date Title
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20190913A1 (es) Derivados aromaticos de sulfonamida
MX336774B (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
PE20120113A1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
PE20121148A1 (es) Compuestos heterociclicos y usos de los mismos
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
WO2009082268A3 (ru) ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20070712A1 (es) Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
PE20120881A1 (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6
PE20150629A1 (es) Derivados de etinilo como moduladores de la actividad del receptor de mglur5
PE20081657A1 (es) Derivados de ftalazina como antagonistas de los receptores de histamina h1
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
HRP20170025T1 (hr) Derivati tetrahidropirolotiazina kao inhibitori bace
PE20060585A1 (es) Derivados de 2-amido-4-feniltiazol como antagonistas de quimiocinas y su preparacion

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed